Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 285

1.

Resistance of Influenza Virus to Antiviral Medications.

Whitley RJ, Monto AS.

Clin Infect Dis. 2019 Sep 20. pii: ciz911. doi: 10.1093/cid/ciz911. [Epub ahead of print] No abstract available.

PMID:
31538179
2.

Lessons from Influenza Pandemics of the last 100 Years.

Monto AS, Fukuda K.

Clin Infect Dis. 2019 Aug 17. pii: ciz803. doi: 10.1093/cid/ciz803. [Epub ahead of print]

PMID:
31420670
3.

Effectiveness of the live attenuated influenza vaccine: was additional of the second type B lineage a step too far?

Monto AS.

Clin Infect Dis. 2019 Aug 13. pii: ciz722. doi: 10.1093/cid/ciz722. [Epub ahead of print] No abstract available.

PMID:
31408517
4.

HAI and NAI titer correlates of inactivated and live attenuated influenza vaccine efficacy.

Gilbert PB, Fong Y, Juraska M, Carpp LN, Monto AS, Martin ET, Petrie JG.

BMC Infect Dis. 2019 May 22;19(1):453. doi: 10.1186/s12879-019-4049-5.

5.

Comparison of a frailty short interview to a validated frailty index in adults hospitalized for acute respiratory illness.

Petrie JG, Martin ET, Zhu Y, Wyatt DG, Kaniclides A, Ferdinands JM, Monto AS, Trabue C, Talbot HK.

Vaccine. 2019 Jun 27;37(29):3849-3855. doi: 10.1016/j.vaccine.2019.05.051. Epub 2019 May 18.

PMID:
31113675
6.

Effectiveness of the Neuraminidase Inhibitors: The Supporting Evidence Increases.

Monto AS.

J Infect Dis. 2019 May 20. pii: jiz157. doi: 10.1093/infdis/jiz157. [Epub ahead of print] No abstract available.

PMID:
31106811
7.

Improving influenza vaccine effectiveness: ways to begin solving the problem.

Monto AS, Petrie JG.

Clin Infect Dis. 2019 May 17. pii: ciz416. doi: 10.1093/cid/ciz416. [Epub ahead of print] No abstract available.

PMID:
31102404
8.

Social patterning of acute respiratory illnesses in the Household Influenza Vaccine Evaluation (HIVE) Study 2014-2015.

Malosh RE, Noppert GA, Zelner J, Martin ET, Monto AS.

Epidemiol Infect. 2019 Jan;147:e185. doi: 10.1017/S0950268819000748.

9.

Data resource profile: Household Influenza Vaccine Evaluation (HIVE) Study.

Monto AS, Malosh RE, Evans R, Lauring AS, Gordon A, Thompson MG, Fry AM, Flannery B, Ohmit SE, Petrie JG, Martin ET.

Int J Epidemiol. 2019 Apr 30. pii: dyz086. doi: 10.1093/ije/dyz086. [Epub ahead of print] No abstract available.

PMID:
31038700
10.

Interim Estimates of 2018-19 Seasonal Influenza Vaccine Effectiveness - United States, February 2019.

Doyle JD, Chung JR, Kim SS, Gaglani M, Raiyani C, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Martin ET, Belongia EA, McLean HQ, Foust A, Sessions W, Berman L, Garten RJ, Barnes JR, Wentworth DE, Fry AM, Patel MM, Flannery B.

MMWR Morb Mortal Wkly Rep. 2019 Feb 15;68(6):135-139. doi: 10.15585/mmwr.mm6806a2.

11.

Influenza Vaccine Effectiveness Against Hospitalization in Fully and Partially Vaccinated Children in Israel; 2015-16, 2016-17, and 2017-18.

Segaloff HE, Leventer-Roberts M, Riesel D, Malosh RE, Feldman BS, Shemer-Avni Y, Key C, Monto AS, Martin ET, Katz MA.

Clin Infect Dis. 2019 Feb 11. doi: 10.1093/cid/ciz125. [Epub ahead of print]

PMID:
30753347
12.

Evaluation of correlates of protection against influenza A(H3N2) and A(H1N1)pdm09 infection: Applications to the hospitalized patient population.

Petrie JG, Martin ET, Truscon R, Johnson E, Cheng CK, McSpadden EJ, Malosh RE, Lauring AS, Lamerato LE, Eichelberger MC, Ferdinands JM, Monto AS.

Vaccine. 2019 Feb 28;37(10):1284-1292. doi: 10.1016/j.vaccine.2019.01.055. Epub 2019 Feb 7.

PMID:
30738647
13.

Effects of Sequential Influenza A(H1N1)pdm09 Vaccination on Antibody Waning.

Zelner J, Petrie JG, Trangucci R, Martin ET, Monto AS.

J Infect Dis. 2019 Jun 5;220(1):12-19. doi: 10.1093/infdis/jiz055.

PMID:
30722022
14.

Antibodies Against Egg- and Cell-Grown Influenza A(H3N2) Viruses in Adults Hospitalized During the 2017-2018 Influenza Season.

Levine MZ, Martin ET, Petrie JG, Lauring AS, Holiday C, Jefferson S, Fitzsimmons WJ, Johnson E, Ferdinands JM, Monto AS.

J Infect Dis. 2019 May 24;219(12):1904-1912. doi: 10.1093/infdis/jiz049.

PMID:
30721982
15.

Neuraminidase, the Forgotten Surface Antigen, Emerges as an Influenza Vaccine Target for Broadened Protection.

Eichelberger MC, Monto AS.

J Infect Dis. 2019 Apr 8;219(Supplement_1):S75-S80. doi: 10.1093/infdis/jiz017.

PMID:
30715357
16.

Effects of Influenza Vaccination in the United States during the 2017-2018 Influenza Season.

Rolfes MA, Flannery B, Chung J, O'Halloran A, Garg S, Belongia EA, Gaglani M, Zimmerman R, Jackson ML, Monto AS, Alden NB, Anderson E, Bennett NM, Billing L, Eckel S, Kirley PD, Lynfield R, Monroe ML, Spencer M, Spina N, Talbot HK, Thomas A, Torres S, Yousey-Hindes K, Singleton J, Patel M, Reed C, Fry AM; U.S. Flu VE Network, the Influenza Hospitalization Surveillance Network (FluSurv-NET), and the Assessment Branch, Immunization Services Division, Centers for Disease Control and Prevention.

Clin Infect Dis. 2019 Feb 2. doi: 10.1093/cid/ciz075. [Epub ahead of print]

PMID:
30715278
17.

Assessing the Protective Potential of H1N1 Influenza Virus Hemagglutinin Head and Stalk Antibodies in Humans.

Christensen SR, Toulmin SA, Griesman T, Lamerato LE, Petrie JG, Martin ET, Monto AS, Hensley SE.

J Virol. 2019 Apr 3;93(8). pii: e02134-18. doi: 10.1128/JVI.02134-18. Print 2019 Apr 15.

18.

Outpatient Antibiotic Prescribing for Acute Respiratory Infections During Influenza Seasons.

Havers FP, Hicks LA, Chung JR, Gaglani M, Murthy K, Zimmerman RK, Jackson LA, Petrie JG, McLean HQ, Nowalk MP, Jackson ML, Monto AS, Belongia EA, Flannery B, Fry AM.

JAMA Netw Open. 2018 Jun 1;1(2):e180243. doi: 10.1001/jamanetworkopen.2018.0243.

19.

Prevention of Influenza Hospitalization Among Adults in the United States, 2015-2016: Results From the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN).

Ferdinands JM, Gaglani M, Martin ET, Middleton D, Monto AS, Murthy K, Silveira FP, Talbot HK, Zimmerman R, Alyanak E, Strickland C, Spencer S, Fry AM; HAIVEN Study Investigators .

J Infect Dis. 2019 Sep 13;220(8):1265-1275. doi: 10.1093/infdis/jiy723.

PMID:
30561689
20.

Influenza vaccine effectiveness among patients with high-risk medical conditions in the United States, 2012-2016.

Shang M, Chung JR, Jackson ML, Jackson LA, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Fry AM, Flannery B.

Vaccine. 2018 Dec 18;36(52):8047-8053. doi: 10.1016/j.vaccine.2018.10.093. Epub 2018 Nov 9.

PMID:
30420119
21.

Hospitalization following outpatient medical care for influenza: US influenza vaccine effectiveness network, 2011-12-2015-16.

Appiah GD, Chung JR, Flannery B, Havers FP, Zimmerman RK, Nowalk MP, Monto AS, Martin ET, Gaglani M, Murthy K, Jackson LA, Jackson ML, McLean HQ, Belongia EA, Fry AM.

Influenza Other Respir Viruses. 2019 Mar;13(2):133-137. doi: 10.1111/irv.12616. Epub 2018 Dec 19.

22.

Study of Healthcare Personnel with Influenza and other Respiratory Viruses in Israel (SHIRI): study protocol.

Hirsch A, Katz MA, Laufer Peretz A, Greenberg D, Wendlandt R, Shemer Avni Y, Newes-Adeyi G, Gofer I, Leventer-Roberts M, Davidovitch N, Rosenthal A, Gur-Arie R, Hertz T, Glatman-Freedman A, Monto AS, Azziz-Baumgartner E, Ferdinands JM, Martin ET, Malosh RE, Neyra QuijandrĂ­a JM, Levine M, Campbell W, Balicer R, Thompson MG; SHIRI workgroup.

BMC Infect Dis. 2018 Nov 6;18(1):550. doi: 10.1186/s12879-018-3444-7.

23.

Influenza Vaccine Effectiveness and Statin Use Among Adults in the United States, 2011-2017.

Havers FP, Chung JR, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Petrie JG, Fry AM, Flannery B.

Clin Infect Dis. 2019 May 2;68(10):1616-1622. doi: 10.1093/cid/ciy780.

PMID:
30371753
24.

Influenza Vaccine Effectiveness in the United States During the 2016-2017 Season.

Flannery B, Chung JR, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Rolfes MA, Spencer S, Fry AM; US Flu VE Investigators .

Clin Infect Dis. 2019 May 17;68(11):1798-1806. doi: 10.1093/cid/ciy775.

25.

Sera from Individuals with Narrowly Focused Influenza Virus Antibodies Rapidly Select Viral Escape Mutations In Ovo.

Davis AKF, McCormick K, Gumina ME, Petrie JG, Martin ET, Xue KS, Bloom JD, Monto AS, Bushman FD, Hensley SE.

J Virol. 2018 Sep 12;92(19). pii: e00859-18. doi: 10.1128/JVI.00859-18. Print 2018 Oct 1.

26.

Severe morbidity among hospitalised adults with acute influenza and other respiratory infections: 2014-2015 and 2015-2016.

Segaloff HE, Petrie JG, Malosh RE, Cheng CK, McSpadden EJ, Ferdinands JM, Lamerato L, Lauring AS, Monto AS, Martin ET.

Epidemiol Infect. 2018 Aug;146(11):1350-1358. doi: 10.1017/S0950268818001486. Epub 2018 Jun 8.

27.

Identification of human vaccinees that possess antibodies targeting the egg-adapted hemagglutinin receptor binding site of an H1N1 influenza vaccine strain.

Garretson TA, Petrie JG, Martin ET, Monto AS, Hensley SE.

Vaccine. 2018 Jun 27;36(28):4095-4101. doi: 10.1016/j.vaccine.2018.05.086. Epub 2018 May 31.

28.

Stochastic processes constrain the within and between host evolution of influenza virus.

McCrone JT, Woods RJ, Martin ET, Malosh RE, Monto AS, Lauring AS.

Elife. 2018 May 3;7. pii: e35962. doi: 10.7554/eLife.35962.

29.

Human coronaviruses and other respiratory infections in young adults on a university campus: Prevalence, symptoms, and shedding.

Davis BM, Foxman B, Monto AS, Baric RS, Martin ET, Uzicanin A, Rainey JJ, Aiello AE.

Influenza Other Respir Viruses. 2018 Apr 16. doi: 10.1111/irv.12563. [Epub ahead of print]

30.

NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines?

Krammer F, Fouchier RAM, Eichelberger MC, Webby RJ, Shaw-Saliba K, Wan H, Wilson PC, Compans RW, Skountzou I, Monto AS.

MBio. 2018 Apr 3;9(2). pii: e02332-17. doi: 10.1128/mBio.02332-17. Review.

31.
32.

Interim Estimates of 2017-18 Seasonal Influenza Vaccine Effectiveness - United States, February 2018.

Flannery B, Chung JR, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Martin ET, Foust A, Sessions W, Berman L, Barnes JR, Spencer S, Fry AM.

MMWR Morb Mortal Wkly Rep. 2018 Feb 16;67(6):180-185. doi: 10.15585/mmwr.mm6706a2.

33.

Influenza vaccine effectiveness in older adults compared with younger adults over five seasons.

Russell K, Chung JR, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Flannery B.

Vaccine. 2018 Feb 28;36(10):1272-1278. doi: 10.1016/j.vaccine.2018.01.045.

34.

Influence of Birth Cohort on Effectiveness of 2015-2016 Influenza Vaccine Against Medically Attended Illness Due to 2009 Pandemic Influenza A(H1N1) Virus in the United States.

Flannery B, Smith C, Garten RJ, Levine MZ, Chung JR, Jackson ML, Jackson LA, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman R, Nowalk MP, Griffin MR, Keipp Talbot H, Treanor JJ, Wentworth DE, Fry AM.

J Infect Dis. 2018 Jun 20;218(2):189-196. doi: 10.1093/infdis/jix634.

35.

Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study.

Lina B, Boucher C, Osterhaus A, Monto AS, Schutten M, Whitley RJ, Nguyen-Van-Tam JS.

Influenza Other Respir Viruses. 2018 Mar;12(2):267-278. doi: 10.1111/irv.12534. Epub 2018 Jan 15.

36.

Maximum likelihood estimation of influenza vaccine effectiveness against transmission from the household and from the community.

Ainslie KEC, Haber MJ, Malosh RE, Petrie JG, Monto AS.

Stat Med. 2018 Mar 15;37(6):970-982. doi: 10.1002/sim.7558. Epub 2017 Nov 28.

37.

Efficacy and Safety of Oseltamivir in Children: Systematic Review and Individual Patient Data Meta-analysis of Randomized Controlled Trials.

Malosh RE, Martin ET, Heikkinen T, Brooks WA, Whitley RJ, Monto AS.

Clin Infect Dis. 2018 May 2;66(10):1492-1500. doi: 10.1093/cid/cix1040.

PMID:
29186364
38.

The risk of lower respiratory tract infection following influenza virus infection: A systematic and narrative review.

Malosh RE, Martin ET, Ortiz JR, Monto AS.

Vaccine. 2018 Jan 2;36(1):141-147. doi: 10.1016/j.vaccine.2017.11.018. Epub 2017 Nov 20. Review.

39.

Influenza Antiviral Prescribing for Outpatients With an Acute Respiratory Illness and at High Risk for Influenza-Associated Complications During 5 Influenza Seasons-United States, 2011-2016.

Stewart RJ, Flannery B, Chung JR, Gaglani M, Reis M, Zimmerman RK, Nowalk MP, Jackson L, Jackson ML, Monto AS, Martin ET, Belongia EA, McLean HQ, Fry AM, Havers FP.

Clin Infect Dis. 2018 Mar 19;66(7):1035-1041. doi: 10.1093/cid/cix922.

40.

The Household Influenza Vaccine Effectiveness Study: Lack of Antibody Response and Protection Following Receipt of 2014-2015 Influenza Vaccine.

Petrie JG, Malosh RE, Cheng CK, Ohmit SE, Martin ET, Johnson E, Truscon R, Eichelberger MC, Gubareva LV, Fry AM, Monto AS.

Clin Infect Dis. 2017 Oct 30;65(10):1644-1651. doi: 10.1093/cid/cix608.

41.

Respiratory syncytial virus hospitalization in middle-aged and older adults.

Malosh RE, Martin ET, Callear AP, Petrie JG, Lauring AS, Lamerato L, Fry AM, Ferdinands J, Flannery B, Monto AS.

J Clin Virol. 2017 Nov;96:37-43. doi: 10.1016/j.jcv.2017.09.001. Epub 2017 Sep 7.

42.

Influenza Vaccine Effectiveness in the United States during the 2015-2016 Season.

Jackson ML, Chung JR, Jackson LA, Phillips CH, Benoit J, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman R, Nowalk MP, Fry AM, Flannery B.

N Engl J Med. 2017 Aug 10;377(6):534-543. doi: 10.1056/NEJMoa1700153.

43.

Prior-Season Vaccination and Risk of Influenza During the 2014-2015 Season in the United States.

Chung JR, Flannery B, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Petrie JG, Martin ET, Monto AS, McLean HQ, Belongia EA, Gaglani M, Fry AM.

J Infect Dis. 2017 Jul 15;216(2):284-285. doi: 10.1093/infdis/jix286. No abstract available.

44.

Application of an Individual-Based Transmission Hazard Model for Estimation of Influenza Vaccine Effectiveness in a Household Cohort.

Petrie JG, Eisenberg MC, Ng S, Malosh RE, Lee KH, Ohmit SE, Monto AS.

Am J Epidemiol. 2017 Dec 15;186(12):1380-1388. doi: 10.1093/aje/kwx217.

45.

Untangling the Effects of Prior Vaccination on Subsequent Influenza Vaccine Effectiveness.

Petrie JG, Monto AS.

J Infect Dis. 2017 Mar 15;215(6):841-843. doi: 10.1093/infdis/jix056. No abstract available.

PMID:
28453852
46.

The Doctrine of Original Antigenic Sin: Separating Good From Evil.

Monto AS, Malosh RE, Petrie JG, Martin ET.

J Infect Dis. 2017 Jun 15;215(12):1782-1788. doi: 10.1093/infdis/jix173. Review.

47.

Report of the WHO technical consultation on the effect of maternal influenza and influenza vaccination on the developing fetus: Montreal, Canada, September 30-October 1, 2015.

Fell DB, Bhutta ZA, Hutcheon JA, Karron RA, Knight M, Kramer MS, Monto AS, Swamy GK, Ortiz JR, Savitz DA.

Vaccine. 2017 Apr 25;35(18):2279-2287. doi: 10.1016/j.vaccine.2017.03.056. Epub 2017 Mar 24.

48.

Moving Toward Improved Influenza Vaccines.

Monto AS.

J Infect Dis. 2017 Feb 15;215(4):500-502. doi: 10.1093/infdis/jiw644. No abstract available.

PMID:
28329073
49.

Interim Estimates of 2016-17 Seasonal Influenza Vaccine Effectiveness - United States, February 2017.

Flannery B, Chung JR, Thaker SN, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Foust A, Sessions W, Berman L, Spencer S, Fry AM.

MMWR Morb Mortal Wkly Rep. 2017 Feb 17;66(6):167-171. doi: 10.15585/mmwr.mm6606a3.

50.

Vaccination has minimal impact on the intrahost diversity of H3N2 influenza viruses.

Debbink K, McCrone JT, Petrie JG, Truscon R, Johnson E, Mantlo EK, Monto AS, Lauring AS.

PLoS Pathog. 2017 Jan 31;13(1):e1006194. doi: 10.1371/journal.ppat.1006194. eCollection 2017 Jan.

Supplemental Content

Loading ...
Support Center